viewTissue Regenix Group PLC

Tissue Regenix MD says the company is at an "exciting period"

Antony Odell, MD of Tissue Regenix (LON:TRX), explains to Proactiveinvestors that the company is at an "exciting period" in its development and, because it is a medical devices company, it is a "lower risk, lower cost and more predictable" business model than a biotech business. Antony also explains that the real benefits of the TRX patented technology are the opportunities from "big unmet needs" in the aging population.

Quick facts: Tissue Regenix Group PLC

Price: 1.175 GBX

Market: AIM
Market Cap: £13.77 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Tissue Regenix Group PLC named herein, including the promotion by the Company of Tissue Regenix Group PLC in any Content on the Site, the...



Tissue Regenix "advancing on many fronts" says CEO after SurgiPure FDA clearance

Antony Odell, chief executive at Tissue Regenix (LON:TRX), talks to Proactive Investors about the US FDA clearance for SurgiPure XD, a skin graft for hernias derived from pig tissue. The group, which already has experience of commercialising products in the US, is planning a commercial...

on 03/09/2016


Trading Update

1 day, 6 hours ago

Second Price Monitoring Extn

1 week, 2 days ago

Price Monitoring Extension

1 week, 2 days ago

Directorate Change

on 11/18/2019

Holding(s) in Company

on 11/14/2019

Holding(s) in Company

on 11/13/2019

2 min read